These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716 [TBL] [Abstract][Full Text] [Related]
5. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535 [TBL] [Abstract][Full Text] [Related]
6. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313 [TBL] [Abstract][Full Text] [Related]
7. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Stock RG; Stone NN Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181 [TBL] [Abstract][Full Text] [Related]
8. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536 [TBL] [Abstract][Full Text] [Related]
9. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. Anderson PR; Hanlon AL; Movsas B; Hanks GE Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540 [TBL] [Abstract][Full Text] [Related]
10. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594 [TBL] [Abstract][Full Text] [Related]
11. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Nguyen PL; Chen MH; Beard CJ; Suh WW; Renshaw AA; Loffredo M; McMahon E; Kantoff PW; D'Amico AV Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1046-52. PubMed ID: 19864082 [TBL] [Abstract][Full Text] [Related]
12. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update. Perez CA; Michalski JM; Mansur D; Lockett MA Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700 [TBL] [Abstract][Full Text] [Related]
13. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma. Sumi M; Ikeda H; Tokuuye K; Kagami Y; Murayama S; Tobisu K; Kakizoe T Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):519-28. PubMed ID: 10974471 [TBL] [Abstract][Full Text] [Related]
14. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066 [TBL] [Abstract][Full Text] [Related]
15. Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer. Akyol F; Selek U; Ozyigit G; Onal C; Akdogan B; Karabulut E; Ozen H J Natl Med Assoc; 2006 Jul; 98(7):1058-61. PubMed ID: 16895273 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. Hirano D; Nagane Y; Satoh K; Mochida J; Sugimoto S; Ichinose T; Takahashi S; Maebayashi T; Saitoh T Int Urol Nephrol; 2010 Mar; 42(1):81-8. PubMed ID: 19449118 [TBL] [Abstract][Full Text] [Related]
17. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335 [TBL] [Abstract][Full Text] [Related]
18. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332 [TBL] [Abstract][Full Text] [Related]
19. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826 [TBL] [Abstract][Full Text] [Related]
20. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]